Fluid debate makes a splash at EURETINA Platform

[caption id="attachment_16398" align="alignleft" width="1024"] Frank Holz[/caption] Key issues relating to the diagnosis and treatment of patients with neovascular age-related macular degeneration were the focus of lively discussion and audience interaction at a packed EURETINA Independent Medical Education Platform event yesterday. Co-moderated by Sebastian Wolf MD, President of EURETINA, and Incoming President Frank Holz MD, the chosen topic of “The Great Fluid Debate: Reviewing treatment outcome goals the wet AMD patient” sought to present a snapshot of current thinking in the management of wet AMD. Welcoming delegates to the new education platform in which the audience would be invited to participate using hand-held voting devices, Prof Wolf said it was encouraging to see the level of interest the topic had generated. “It is great to see such a huge audience for this new interactive format that we will maintain in the coming years. This is a particularly relevant topic as we try to manage our patients with wet AMD,” he said. Dr Holz opened the session with some preliminary indicators from the EURETINA Survey Data 2019, which he said was already providing valuable insights into clinical practice in Europe and further afield. “The survey data gives us very good ideas on what is common practice, standards of care and in identifying unmet needs,” he said. Prof Wolf then gave delegates a comprehensive overview of the utility of multimodal imaging, followed by Martin Zinkernagel MD, who presented the arguments in favour of a zero-tolerance approach to the presence of all types of fluid in the treatment of wet AMD. Pravin Dugel MD put recent OCT fluid analyses and their clinical implications into context, while Ramin Tadayoni MD presented the counter arguments as to why a small amount of sub-retinal fluid may not be detrimental to vision in some patients.

Tags: EURETINA Independent Medical Education Platform, neovascular amd